ELI LILLY & Co is 760.7x more valuable than UroGen Pharma Ltd. by market capitalization ($1.093 T vs $1.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | URGN | LLY |
|---|---|---|
| Market cap | $1.44 B | $1.093 T |
| US-listed rank | #2378 | #11 |
| Revenue (latest FY) | $109.79M | $65.18B |
| Net income (latest FY) | -$153.49M | $20.64B |
| Net margin | -139.8% | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 549 | 989 |
ELI LILLY & Co is 760.7x more valuable than UroGen Pharma Ltd. by market capitalization ($1.093 T vs $1.44 B).
In their latest fiscal years, UroGen Pharma Ltd. reported $109.79M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: UroGen Pharma Ltd. and ELI LILLY & Co, or browse the full rankings.